<code id='60D37334D0'></code><style id='60D37334D0'></style>
      • <acronym id='60D37334D0'></acronym>
      <center id='60D37334D0'><center id='60D37334D0'><tfoot id='60D37334D0'></tfoot></center><abbr id='60D37334D0'><dir id='60D37334D0'><tfoot id='60D37334D0'></tfoot><noframes id='60D37334D0'>
      • <optgroup id='60D37334D0'><strike id='60D37334D0'><sup id='60D37334D0'></sup></strike><code id='60D37334D0'></code></optgroup>
        5. <b id='60D37334D0'><label id='60D37334D0'><select id='60D37334D0'><dt id='60D37334D0'><span id='60D37334D0'></span></dt></select></label></b><u id='60D37334D0'></u>
          <i id='60D37334D0'><strike id='60D37334D0'><tt id='60D37334D0'><pre id='60D37334D0'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / fashion / knowledge      
           
     
           
      
          knowledge 
           
      
           
      
           
       2025-09-27 09:51:23 
   
      
           
      
           
                        
          knowledge  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      Page View：271
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Aspartame and sugar
                                
                            
          Next article：  
                                      
                                          Tori Bowie and the unacceptable rates of Black maternal death
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles